JPMorgan Chase & Co. Has $5.60 Million Stock Holdings in Organon & Co. (NYSE:OGN)

JPMorgan Chase & Co. lowered its position in Organon & Co. (NYSE:OGN - Free Report) by 40.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 375,008 shares of the company's stock after selling 258,322 shares during the period. JPMorgan Chase & Co. owned 0.15% of Organon & Co. worth $5,595,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Elo Mutual Pension Insurance Co bought a new stake in shares of Organon & Co. during the fourth quarter valued at approximately $326,000. Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Organon & Co. by 8.9% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 578,683 shares of the company's stock valued at $8,634,000 after buying an additional 47,176 shares during the period. EntryPoint Capital LLC bought a new position in Organon & Co. in the fourth quarter valued at approximately $417,000. Vanguard Group Inc. grew its holdings in Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock worth $453,593,000 after acquiring an additional 218,165 shares during the period. Finally, Napatree Capital LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at $445,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on OGN shares. Barclays decreased their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Morgan Stanley cut their price target on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $20.60.

Organon & Co. Stock Up 2.7 %

NYSE OGN traded up $0.29 during trading hours on Friday, reaching $11.11. 2,927,325 shares of the company's stock were exchanged, compared to its average volume of 2,654,936. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a one year low of $10.75 and a one year high of $23.10. The company's 50-day moving average is $14.25 and its two-hundred day moving average is $15.39. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of 3.34, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 10.08%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s payout ratio is 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.